m6A modification: a new avenue for anti-cancer therapy

Abstract

To date, over 170 different kinds of chemical modifications on RNAs have been identified, some of which are involved in multiple aspects of RNA fate, ranging from RNA processing, nuclear export, translation, and RNA decay. m 6A, also known as N 6-methyladenosin, is a prominent internal RNA modification that is catalyzed primarily by the METTL3-METTL14-WTAP methyltransferase complex in higher eukaryotic mRNA and long noncoding RNA (lncRNA). In recent years, abnormal m 6A modification has been linked to the occurrence, development, progression, and prognosis of the majority of cancers. In this review, we provide an update on the most recent m 6A modification discoveries as well as the critical roles of m 6A modification in cancer development and progression. We summarize the mechanisms of m 6A involvement in cancer and list potential cancer therapy inhibitors that target m6A regulators such as “writer” METTL3 and “eraser” FTO.

Deciphering RNA m6A regulation in aging: Perspectives on current advances and future directions

“…RNA m 6 A modification is dynamically regulated by “writers” such as METTL3 and METTL14, “erasers” such as FTO and ALKBH5, and “readers” such as YTH family members and IGF2 binding proteins. These regulators function to control splicing, nuclear export, stability, and translation of target RNAs involved in various biological processes (Bai et al, 2023 ; Deng et al, 2018 ; Huang et al, 2020 ; Roignant & Soller, 2017 ). Recently, there has been increasing evidence for the involvement of m 6 A regulation in cellular senescence and other aging‐related processes (Bao et al, 2023 ; Casella et al, 2019 ; Jiapaer et al, 2022 ; Sun, Cheng, et al, 2022 ; Wu et al, 2022 ; Zhang & Xia, 2023 ).…”